Tag: MaaT013
MaaT Pharma presents positive data for MaaT013 at 18 months at EBMT 2024 showing a clear advantage in terms of overall survival in aGvHD in its compassionate access program – 04/15/2024 at 07:40
MaaT Pharma presents positive data for MaaT013 at 18 months at EBMT 2024 showing a clear advantage in terms of overall survival in aGvHD in its compassionate access program:• Positive…
MaaT Pharma presents positive results for MaaT013, its most advanced drug candidate, at ASH 2023 and details the ongoing Phase 2b trial evaluating MaaT033 – 11/12/2023 at 07:38
MaaT Pharma presents positive results for MaaT013, its most advanced drug candidate, at ASH 2023 and details the ongoing Phase 2b trial evaluating MaaT033 • Positive efficacy results from 111…
MaaT Pharma: presentation of two posters for MaaT013 and MaaT033 at the next ASH conference
By Hector Chaunu Published on 02/11/2023 at 6:22 p.m. Photo credit © ChaunuPictures (Boursier.com) — MaaT Pharmaa late-stage…
MaaT Pharma announces the presentation of two posters for MaaT013 and MaaT033 at the next ASH conference – 02/11/2023 at 6:12 p.m.
MaaT Pharma announces the presentation of two posters for MaaT013 and MaaT033 at the next ASH conference • The first poster will present the results of 111 patients with acute…
MaaT Pharma to Present Clinical Data for MaaT013 and MaaT033 at EBMT’s 49th Annual Meeting
By Hector Chaunu Published on 04/11/2023 at 22:04 Photo credit © ChaunuPictures (Boursier.com) — MaaT Pharmaa French late-stage…
MaaT Pharma to Present Clinical Data for MaaT013 and MaaT033 at EBMT’s 49th Annual Meeting – 2023-04-11 18:15
MaaT Pharma to Present Clinical Data for MaaT013 and MaaT033 at EBMT’s 49th Annual Meeting • The data was previously shared at the American Society of Hematology (ASH) Annual Meeting…
MaaT Pharma Presents Promising Consolidated Clinical Data for MaaT013 at ASH’s 64th Annual Meeting – 12/10/2022 at 5:40 PM
MaaT Pharma presented today, at the annual meeting of the American Society of Hematology (ASH), the world’s largest hematology meeting, promising consolidated results from 81 patients with acute Gastrointestinal (GI)…
MaaT Pharma Announces Update on Clinical Trial Authorization Application Filed with the FDA for MaaT013 in Patients With Acute Graft Versus Host Disease
MaaT Pharma (EURONEXT: MAAT), a French clinical-stage biotechnology company pioneering the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving the survival of cancer patients, announces today that it has…
MaaT Pharma announces the initiation of an investigator-sponsored Phase 2a clinical trial evaluating MaaT013 in combination with immunotherapies for patients with melanoma – 04/07/2022 at 18:10
MaaT Pharma (EURONEXT: MAAT – the “Company”), a French late-stage biotechnology company, a pioneer in the development of drugs to restore the gut microbiota to improve the survival of cancer…
MaaT Pharma announces the treatment of a first patient in the Phase 3 “ARES” clinical study evaluating MaaT013 in the treatment of acute graft versus host disease – 03/28/2022 at 18:15
Pivotal Phase 3 Clinical Trial Investigates Efficacy of MaaT Pharma’s Most Advanced Microbiome Ecosystem Therapy, MaaT013, as a Third-Line Treatment in Patients with Acute Graft-vs-Host Disease with Gastrointestinal Component -intestinal…
MaaT Pharma to present promising clinical data for MaaT013, its most advanced drug candidate, at the 48th annual meeting of the EBMT – 03/17/2022 at 18:15
MaaT Pharma announces today that promising results from its Phase 2 clinical trial HERACLES (n=24) and its compassionate access program (n=52) for its most advanced microbiota drug candidate, MaaT013, will…